Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923163 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL17225268 | 0.78 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL17225290 | 0.77 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL17225310 | 0.77 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL25319824 | 0.73 | APLNR (0.35) | APLNR | |
| SCHEMBL25317072 | 0.73 | APLNR (0.33) | APLNR | |
| SCHEMBL19336769 | 0.73 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL23881417 | 0.71 | APLNR (0.32) | APLNR | |
| SCHEMBL9923367 | 0.71 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9923053 | 0.71 | CYP1A2 (0.37) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | CYP1A2 382/4885CYP2D6 76/4885CYP19A1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.